Anne B Satterthwaite1. 1. Department of Internal Medicine, Rheumatic Diseases Division and Department of Immunology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8884, USA. anne.satterthwaite@utsouthwestern.edu.
Abstract
PURPOSE OF THE REVIEW: Systemic lupus erythematosus (SLE) is driven by nucleic acid-containing antigens that stimulate endosomal TLRs. We review new advances in our understanding of how TLR7 signaling in B cells drives autoimmunity. RECENT FINDINGS: Pathogenic B cell responses to TLR7 engagement are shaped by the disease-associated cytokine environment. TLR7, IFNγ, and IL-21 together promote the formation of autoreactive germinal centers and the ABC/DN2 B cell subset. BAFF and type 1 IFNs enhance autoantibody production from transitional B cells in concert with TLR7. TLR7 signaling components STAT1, BANK1, IRF5, SLC15A4, and CXorf21/TASL are associated genetically with SLE and important for lupus development in mice, while role of T-bet is controversial. Proper control of TLR7 trafficking by UNC93B1, syntenin-1, and αvβ3 integrin is critical for preventing autoimmunity. A better understanding of TLR7 signaling has revealed potential new therapeutic approaches for SLE, several of which are being tested in animal models or clinical trials.
PURPOSE OF THE REVIEW: Systemic lupus erythematosus (SLE) is driven by nucleic acid-containing antigens that stimulate endosomal TLRs. We review new advances in our understanding of how TLR7 signaling in B cells drives autoimmunity. RECENT FINDINGS: Pathogenic B cell responses to TLR7 engagement are shaped by the disease-associated cytokine environment. TLR7, IFNγ, and IL-21 together promote the formation of autoreactive germinal centers and the ABC/DN2 B cell subset. BAFF and type 1 IFNs enhance autoantibody production from transitional B cells in concert with TLR7. TLR7 signaling components STAT1, BANK1, IRF5, SLC15A4, and CXorf21/TASL are associated genetically with SLE and important for lupus development in mice, while role of T-bet is controversial. Proper control of TLR7 trafficking by UNC93B1, syntenin-1, and αvβ3 integrin is critical for preventing autoimmunity. A better understanding of TLR7 signaling has revealed potential new therapeutic approaches for SLE, several of which are being tested in animal models or clinical trials.
Authors: Srividya Subramanian; Katalin Tus; Quan-Zhen Li; Andrew Wang; Xiang-Hong Tian; Jinchun Zhou; Chaoying Liang; Guy Bartov; Lisa D McDaniel; Xin J Zhou; Roger A Schultz; Edward K Wakeland Journal: Proc Natl Acad Sci U S A Date: 2006-06-15 Impact factor: 11.205
Authors: Shaun W Jackson; Nicole E Scharping; Nikita S Kolhatkar; Socheath Khim; Marc A Schwartz; Quan-Zhen Li; Kelly L Hudkins; Charles E Alpers; Denny Liggitt; David J Rawlings Journal: J Immunol Date: 2014-04-07 Impact factor: 5.422
Authors: Prapaporn Pisitkun; Jonathan A Deane; Michael J Difilippantonio; Tatyana Tarasenko; Anne B Satterthwaite; Silvia Bolland Journal: Science Date: 2006-05-18 Impact factor: 47.728
Authors: Elizabeth A Leadbetter; Ian R Rifkin; Andreas M Hohlbaum; Britte C Beaudette; Mark J Shlomchik; Ann Marshak-Rothstein Journal: Nature Date: 2002-04-11 Impact factor: 49.962
Authors: Jonathan A Deane; Prapaporn Pisitkun; Rebecca S Barrett; Lionel Feigenbaum; Terrence Town; Jerrold M Ward; Richard A Flavell; Silvia Bolland Journal: Immunity Date: 2007-11-08 Impact factor: 31.745
Authors: Sun-Hee Hwang; Huiyin Lee; Miwako Yamamoto; Leigh A Jones; Jivanaah Dayalan; Richard Hopkins; Xin J Zhou; Felix Yarovinsky; John E Connolly; Maria A Curotto de Lafaille; Edward K Wakeland; Anna-Marie Fairhurst Journal: J Immunol Date: 2012-11-12 Impact factor: 5.422
Authors: Sathi Babu Chodisetti; Adam J Fike; Phillip P Domeier; Harinder Singh; Nicholas M Choi; Chelsea Corradetti; Yuka Imamura Kawasawa; Timothy K Cooper; Roberto Caricchio; Ziaur S M Rahman Journal: J Immunol Date: 2020-01-03 Impact factor: 5.422
Authors: Christina M Lau; Courtney Broughton; Abigail S Tabor; Shizuo Akira; Richard A Flavell; Mark J Mamula; Sean R Christensen; Mark J Shlomchik; Gregory A Viglianti; Ian R Rifkin; Ann Marshak-Rothstein Journal: J Exp Med Date: 2005-10-31 Impact factor: 14.307